» Articles » PMID: 28732457

Long-term Recurrence of Venous Thromboembolism After Short-term Treatment of Symptomatic Isolated Distal Deep Vein Thrombosis: A Cohort Study

Overview
Journal Vasc Med
Publisher Sage Publications
Date 2017 Jul 23
PMID 28732457
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Isolated distal deep vein thrombosis (IDDVT) is a common clinical manifestation of venous thromboembolism (VTE). However, there are only scant and heterogeneous data available on the long-term risk of recurrent VTE after IDDVT, and the optimal therapeutic management remains uncertain. We carried out a retrospective cohort study of consecutive patients diagnosed with symptomatic IDDVT between 2004 and 2011, according to a predefined short-term treatment protocol (low molecular weight heparin (LMWH) for 4-6 weeks). The primary outcome was the occurrence of recurrent VTE. A total of 321 patients were enrolled. IDDVT was associated with a transient risk factor or cancer in 165 (51.4%) and 56 (17.4%) patients, respectively. LMWH was administered for 4-6 weeks to 280 patients (87.2%), who were included in the primary analysis. Overall, during a mean follow-up of 42.3 months, 42 patients (15%) developed recurrent VTE, which occurred as proximal DVT or PE in 21 cases. The recurrence rate of VTE per 100 patient-years was 3.5 in patients with transient risk factors, 7.2 in patients with unprovoked IDDVT, and 5.9 in patients with cancer ( p=0.018). At multivariable analysis, unprovoked IDDVT and previous VTE were significantly associated with recurrent VTE (HR 2.16, 95% CI 1.12-4.16 and HR 1.97, 95% CI 1.01-3.86, respectively). In conclusion, the long-term risk of recurrent VTE after IDDVT treated for 4-6 weeks is not negligible, in particular in patients with unprovoked IDDVT or cancer. Further studies are needed to clarify whether a longer, but definite treatment duration effectively prevents these recurrences.

Citing Articles

Generation of a Predictive Clinical Model for Isolated Distal Deep Vein Thrombosis (ICMVT) Detection.

Xu Y, Xu M, Zheng X, Jin F, Meng B Med Sci Monit. 2023; 29:e942840.

PMID: 38160251 PMC: 10765549. DOI: 10.12659/MSM.942840.


Comparison of clinical outcomes among patients with isolated axial vs muscular calf vein thrombosis: A systematic review and meta-analysis.

Wang C, Shi C, Guo R, Wu T J Vasc Surg Venous Lymphat Disord. 2023; 12(2):101727.

PMID: 38043681 PMC: 11523313. DOI: 10.1016/j.jvsv.2023.101727.


The clinical outcomes of different doses of rivaroxaban in patients with isolated distal deep vein thrombosis.

Wang B, Wang Q, Ji Y, Zhang Y, Qiao T J Vasc Surg Venous Lymphat Disord. 2023; 12(2):101653.

PMID: 37490950 PMC: 11523455. DOI: 10.1016/j.jvsv.2023.07.008.


Rivaroxaban treatment for six weeks versus three months in patients with symptomatic isolated distal deep vein thrombosis: randomised controlled trial.

Ageno W, Bertu L, Bucherini E, Camporese G, Dentali F, Iotti M BMJ. 2022; 379:e072623.

PMID: 36520715 PMC: 9682494. DOI: 10.1136/bmj-2022-072623.


Association of Remote History of Venous Thrombosis With Risk of Venous Thrombosis After Age 70 Years.

Wang H, Cushman M, Rosendaal F, van Hylckama Vlieg A JAMA Netw Open. 2022; 5(3):e224205.

PMID: 35333359 PMC: 8956975. DOI: 10.1001/jamanetworkopen.2022.4205.